25 May 2017 16:24
Vectura Group plc
Results of the Annual General Meeting held on 25 May 2017 at the offices of Clifford Chance LLP, 10 Upper Bank Street, London E14 5JJ.
Chippenham, UK, 25 May 2017: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:
Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes withheld* | |||||
1 | To receive the Company's Report and Accounts for the nine months ended 31 December 2016 including the independent auditor's report |
| 97.43 | 14,208,182 | 2.57 | 29,991 | ||||
2 | To approve the Directors' Remuneration Policy | 518,828,772 | 96.56 | 18,505,659 | 3.44 | 16,469,480 | ||||
3 | To receive and approve the Directors' Remuneration Report for the nine months ended 31 December 2016 (excluding the Remuneration Policy) | 522,296,809 | 95.78 | 23,001,558 | 4.22 | 8,505,545 | ||||
4 | To re-elect Dr P Andersson | 550,427,165 | 99.40 | 3,296,566 | 0.60 | 80,182 | ||||
5 | To re-elect Bruno Angelici | 545,863,232 | 98.64 | 7,504,313 | 1.36 | 436,369 | ||||
6 | To re-elect Frank Condella | 521,328,310 | 94.15 | 32,395,663 | 5.85 | 79,942 | ||||
7 | To re-elect Andrew Derodra | 545,489,090 | 98.51 | 8,223,282 | 1.49 | 91,544 | ||||
8 | To re-elect Dr Susan Foden | 526,562,922 | 98.10 | 10,219,297 | 1.90 | 17,021,698 | ||||
9 | To re-elect James Ward-Lilley | 548,000,029 | 98.97 | 5,712,651 | 1.03 | 91,238 | ||||
10 | To re-elect Neil Warner | 552,862,847 | 99.84 | 861,229 | 0.16 | 79,843 | ||||
11 | To re-elect Dr Thomas Werner | 553,222,872 | 99.91 | 490,055 | 0.09 | 90,993 | ||||
12 | To appoint KPMG LLP as the Company's Auditor | 553,609,848 | 99.97 | 166,125 | 0.03 | 27,948 | ||||
13 | To authorise the Audit Committee to determine the auditor's remuneration | 553,687,129 | 99.98 | 109,800 | 0.02 | 6,993 | ||||
14 | To authorise political donations and expenditure | 532,550,792 | 96.17 | 21,184,033 | 3.83 | 68,757 | ||||
15 | To authorise the Directors to allot shares in the Company pursuant to section 551 of the Companies Act 2006 | 537,069,120 | 96.99 | 16,680,629 | 3.01 | 35,688 | ||||
16 | To approve the Rules of the Deferred Share Bonus Plan | 543,417,948 | 98.13 | 10,331,467 | 1.87 | 54,510 | ||||
17 | To authorise the disapplication of pre-emption rights | 547,458,293 | 98.87 | 6,284,433 | 1.13 | 61,200 | ||||
18 | To authorise the disapplication of pre-emption rights in relation to an acquisition or other capital investment | 507,736,477 | 91.69 | 46,006,450 | 8.31 | 61,000 | ||||
19 | To authorise market purchases of the Company's own shares | 544,461,196 | 98.31 | 9,334,145 | 1.69 | 8,587 | ||||
20 | To authorise the calling of any general meetings of the Company other than an Annual General Meeting by notice of at least 14 clear days | 546,503,889 | 98.68 | 7,297,055 | 1.32 | 2,537 |
*NB: The percentage of votes cast for and against excludes withheld votes.
Enquiries:
Vectura Group plc | +44 (0)1249 667700 |
John Murphy Company Secretary
| |
One Prospect West Chippenham Wiltshire SN14 6FH
| |
Consilium Strategic Communications | +44 (0)20 3709 5700 |
Mary-Jane Elliot / Sue Stuart / Jessica Hodgson |
|
Notes for Editors:
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.
Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com.